Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial

BACKGROUND: Dose-dense sequential chemotherapy including anthracyclines and taxanes has been established in the adjuvant setting of high-risk operable breast cancer. However, the preferable taxane and optimal schedule of administration in a dose-dense regimen have not been defined yet. METHODS: From...

Descripción completa

Detalles Bibliográficos
Autores principales: Fountzilas, George, Dafni, Urania, Papadimitriou, Christos, Timotheadou, Eleni, Gogas, Helen, Eleftheraki, Anastasia G, Xanthakis, Ioannis, Christodoulou, Christos, Koutras, Angelos, Papandreou, Christos N, Papakostas, Pavlos, Miliaras, Spyros, Markopoulos, Christos, Dimitrakakis, Constantine, Korantzopoulos, Panagiotis, Karanikiotis, Charisios, Bafaloukos, Dimitrios, Kosmidis, Paris, Samantas, Epaminontas, Varthalitis, Ioannis, Pavlidis, Nicholas, Pectasides, Dimitrios, Dimopoulos, Meletios-Athanassios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223601/
https://www.ncbi.nlm.nih.gov/pubmed/25026897
http://dx.doi.org/10.1186/1471-2407-14-515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223601/
https://www.ncbi.nlm.nih.gov/pubmed/25026897
http://dx.doi.org/10.1186/1471-2407-14-515

Ejemplares similares